Agios Pharmaceuticals, Inc. (0HB0.L)
USD 26.46
(-7.16%)
USD 26.46
(-7.16%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -31.21 Million USD | 41.76% |
| 2022 | -53.6 Million USD | 49.45% |
| 2021 | -106.03 Million USD | -376.83% |
| 2020 | -22.23 Million USD | -167.94% |
| 2019 | 32.73 Million USD | 146.43% |
| 2018 | -70.5 Million USD | 31.37% |
| 2017 | -102.72 Million USD | 36.1% |
| 2016 | -160.75 Million USD | -124.0% |
| 2015 | -71.76 Million USD | -411.47% |
| 2014 | -14.03 Million USD | 80.39% |
| 2013 | -71.56 Million USD | 21.62% |
| 2012 | -91.29 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -35.75 Million USD | 29.08% |
| 2024 Q3 | -237.41 Million USD | -563.94% |
| 2024 Q1 | -50.41 Million USD | -211.04% |
| 2023 Q3 | 11.16 Million USD | 292.27% |
| 2023 FY | -16.2 Million USD | 69.76% |
| 2023 Q4 | -16.2 Million USD | -245.18% |
| 2023 Q1 | -21.8 Million USD | 59.33% |
| 2023 Q2 | -5.8 Million USD | 73.36% |
| 2022 Q3 | -33.52 Million USD | -1376.66% |
| 2022 Q2 | 2.62 Million USD | -81.99% |
| 2022 Q1 | 14.58 Million USD | 113.75% |
| 2022 FY | -53.6 Million USD | 49.45% |
| 2022 Q4 | -53.6 Million USD | -59.88% |
| 2021 Q2 | -867.21 Million USD | 51.4% |
| 2021 Q4 | -106.03 Million USD | 64.78% |
| 2021 Q3 | -301.08 Million USD | 65.28% |
| 2021 FY | -106.03 Million USD | -376.83% |
| 2021 Q1 | -1.78 Billion USD | -5918.88% |
| 2020 Q3 | 253.37 Million USD | 340.91% |
| 2020 FY | -22.23 Million USD | -167.94% |
| 2020 Q4 | -29.64 Million USD | -111.7% |
| 2020 Q1 | 15.48 Million USD | -40.01% |
| 2020 Q2 | 57.46 Million USD | 271.03% |
| 2019 Q2 | 26.49 Million USD | 170.77% |
| 2019 FY | 32.73 Million USD | 146.43% |
| 2019 Q4 | 25.81 Million USD | -2.16% |
| 2019 Q3 | 26.38 Million USD | -0.4% |
| 2019 Q1 | -37.43 Million USD | 46.9% |
| 2018 Q4 | -70.5 Million USD | 54.94% |
| 2018 Q1 | -364.46 Million USD | -254.8% |
| 2018 FY | -70.5 Million USD | 31.37% |
| 2018 Q2 | -210.32 Million USD | 42.29% |
| 2018 Q3 | -156.47 Million USD | 25.6% |
| 2017 Q2 | -138.71 Million USD | 30.74% |
| 2017 FY | -102.72 Million USD | 36.1% |
| 2017 Q4 | -102.72 Million USD | 22.61% |
| 2017 Q1 | -200.27 Million USD | -24.59% |
| 2017 Q3 | -132.74 Million USD | 4.31% |
| 2016 Q1 | -39.03 Million USD | 45.61% |
| 2016 Q3 | -285.5 Million USD | -21.98% |
| 2016 Q2 | -234.04 Million USD | -499.58% |
| 2016 Q4 | -160.75 Million USD | 43.69% |
| 2016 FY | -160.75 Million USD | -124.0% |
| 2015 Q4 | -71.76 Million USD | 10.35% |
| 2015 Q3 | -80.04 Million USD | -10.36% |
| 2015 Q2 | -72.53 Million USD | -105.73% |
| 2015 Q1 | -35.25 Million USD | -151.27% |
| 2015 FY | -71.76 Million USD | -411.47% |
| 2014 Q1 | -32.83 Million USD | 54.11% |
| 2014 Q3 | -70.04 Million USD | 35.29% |
| 2014 Q4 | -14.03 Million USD | 79.97% |
| 2014 FY | -14.03 Million USD | 80.39% |
| 2014 Q2 | -108.24 Million USD | -229.65% |
| 2013 Q1 | -83.37 Million USD | 8.67% |
| 2013 Q4 | -71.56 Million USD | 32.5% |
| 2013 Q3 | -106.01 Million USD | -36.82% |
| 2013 FY | -71.56 Million USD | 21.62% |
| 2013 Q2 | -77.48 Million USD | 7.07% |
| 2012 Q4 | -91.29 Million USD | 0.0% |
| 2012 FY | -91.29 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 69.678% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 115.761% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 197.905% |
| bluebird bio, Inc. | 108.57 Million USD | 128.753% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -246.24% |
| Imunon, Inc. | -4.69 Million USD | -564.294% |
| Editas Medicine, Inc. | -87.11 Million USD | 64.166% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 100.243% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 101.488% |
| Myriad Genetics, Inc. | 88.1 Million USD | 135.434% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 117.607% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 6.89% |
| Verastem, Inc. | -37.27 Million USD | 16.259% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 100.379% |
| Waters Corporation | 1.96 Billion USD | 101.592% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 100.116% |
| Biogen Inc. | 6.28 Billion USD | 100.496% |
| Nektar Therapeutics | 210.24 Million USD | 114.848% |
| Perrigo Company plc | 3.32 Billion USD | 100.94% |
| Dynavax Technologies Corporation | 106.63 Million USD | 129.275% |
| Illumina, Inc. | 1.21 Billion USD | 102.571% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 548.0% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 72.59% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 121.518% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 534.354% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 108.242% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -339.676% |
| Evolus, Inc. | 63.7 Million USD | 149.0% |
| Adicet Bio, Inc. | -142 Million USD | 78.017% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 15.18% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | -15.192% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 106.806% |
| FibroGen, Inc. | 56.76 Million USD | 154.991% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 102.726% |
| OPKO Health, Inc. | 230.68 Million USD | 113.532% |
| Homology Medicines, Inc. | 18.43 Million USD | 269.317% |
| Geron Corporation | 14.76 Million USD | 311.483% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 101.969% |
| Exelixis, Inc. | -73.05 Million USD | 57.266% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 42.464% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 79.33% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 71.978% |
| Zoetis Inc. | 4.76 Billion USD | 100.656% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 84.378% |
| Abeona Therapeutics Inc. | -10.07 Million USD | -209.969% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.674% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | -114.226% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 102.961% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 103.224% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 76.945% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 102.261% |
| Blueprint Medicines Corporation | 702.83 Million USD | 104.442% |
| Insmed Incorporated | 721.62 Million USD | 104.326% |
| TG Therapeutics, Inc. | 17.86 Million USD | 274.768% |
| Incyte Corporation | -3.17 Billion USD | 99.017% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 104.076% |